Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mathew D Minardi"'
Autor:
Jaroslaw Mazurek, Marcel Hoffmann, Ana Fernandez Casares, D. Phillip Cox, Mathew D. Minardi, Josh Sasine
Publikováno v:
Acta Crystallographica Section E: Crystallographic Communications, Vol 72, Iss 5, Pp 730-733 (2016)
Conditions to obtain two polymorphic forms by crystallization from solution were determined for the analgesic drug hydromorphone [C17H19NO3; systematic name: (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-
Externí odkaz:
https://doaj.org/article/2773389c7854441384ffd46d1e3c9ff0
Publikováno v:
Acta Crystallographica Section E, Vol 70, Iss 6, Pp o635-o635 (2014)
In the crystal structure of a semi-synthetic opioid drug buprenorphine, C29H41NO4 {systematic name: (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol}, the cyclopropylmethyl g
Externí odkaz:
https://doaj.org/article/0efa2cbc20c346aa9937a86430beeb1f
Autor:
Marcel Hoffmann, Ana Fernandez Casares, D. Phillip Cox, Josh Sasine, Jaroslaw Mazurek, Mathew D. Minardi
Publikováno v:
Acta Crystallographica Section E: Crystallographic Communications
Acta Crystallographica Section E: Crystallographic Communications, Vol 72, Iss 5, Pp 730-733 (2016)
Acta Crystallographica Section E: Crystallographic Communications, Vol 72, Iss 5, Pp 730-733 (2016)
Conditions to obtain two polymorphic forms by crystallization from solution were determined for the analgestic drug hydromorphone. In both polymorphs, the hydromorphone molecules adopt very similar conformations with some small differences obse
Autor:
George R. Pettit, Heidi J Rosenberg, Timothy J Cuthbertson, Michael C Bibby, Sandie W Martin, Mathew D Minardi, Jean-Charles Chapuis, Robin K. Pettit, M. Katherine Jung, Ernest Hamel
Publikováno v:
Journal of Natural Products. 68:1450-1458
The present SAR study of combretastatin A-3 (3a) focused on replacement of the 3-hydroxyl group by a series of halogens. That approach with Z-stilbenes resulted in greatly enhanced (>10-100-fold) cancer cell growth inhibition against a panel of human
Publikováno v:
Journal of natural products. 73(3)
Human cancer and other clinical trials under development employing combretastatin A-4 phosphate (1b, CA4P) should benefit from the availability of a [(11)C]-labeled derivative for positron emission tomography (PET). In order to obtain a suitable prec